Login to Your Account

Polyphor gets $40M to move murepavadin into pivotal study in pneumonia

By Cormac Sheridan
Staff Writer

Wednesday, April 12, 2017

DUBLIN – Investors in Polyphor Ltd. have kept their faith in the company's first-in-class antibiotic therapy murepavadin by pumping in CHF40 million. 

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription